SLC10A2 and metabolic disease: NTCP (SLC10A1) and ASBT (SLC10A2), as bile acid transporters, are indeed associated with the occurrence and development of metabolic diseases and may be potential therapeutic targets (Donkers et al., 2019b; Yang et al., 2020).